From the website, "BLASTX search protein databases using a translated nucleotide query." What does "a translated nucleotide query" really mean here? Shouldn't be a initial genomic DNA sequence, right? A mRNA sequence with "U" replaced by "T"? Would appreciate any help or hint!
-
-
The input (query) which you provide to BLASTX is standard DNA sequence (AGCTN). The BLASTX program then translates this input into protein sequence; the translation is performed for all six possible reading frames. This is what is meant by "translated nucleotide query". The translated sequences are then compared to the protein database you have specified. I don't know off the top of my head how BLASTX deals RNA sequences (AGCUN). -
Thanks.
Yes, I understand the input should be a standard DNA sequence. The thing confusing me is this DNA sequence should only compose of protein coding parts, or it just a common DNA sequence. That's why I mentioned mRNA sequence with "U" replaced by "T".
Actually, I got a initial genomic DNA sequence data, I try to BLAST it vs. a protein database to have functional analysis, just wondering if i need more steps, or can straightly take BLASTX running.Comment
-
Hello
No, you don't need any more steps, you can just submit as is to the protein database. Although, if this is a non-coding region, you won't find much.Comment
-
Thanks. Let me take a try.
Have a good day to everyone!Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment